Last reviewed · How we verify
Active drug group
Active drug group is a Small molecule drug developed by Tasly Pharmaceutical Group Co., Ltd. It is currently FDA-approved. Also known as: JS1-1-01 placebo pills; Duloxetine hydrochloride enteric coated capsule, Ropivacaine.
This is a broad category descriptor rather than a specific drug, referring to any pharmaceutical compound with active therapeutic properties marketed by Tasly Pharmaceutical Group.
VDJ001 is a recombinant humanized anti-interleukin-6 receptor monoclonal antibody injection used to treat conditions such as rheumatoid arthritis, hypertension, metabolic syndrome, chronic heart failure, and Alzheimer's disease. It is a vaccine component that induces an immune response, although its exact mechanism of action is not specified.
At a glance
| Generic name | Active drug group |
|---|---|
| Also known as | JS1-1-01 placebo pills; Duloxetine hydrochloride enteric coated capsule, Ropivacaine |
| Sponsor | Tasly Pharmaceutical Group Co., Ltd |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Without a specific drug name or brand, the mechanism cannot be determined. Tasly Pharmaceutical Group Co., Ltd manufactures multiple marketed drugs across different therapeutic areas. A specific drug name is required to provide accurate mechanistic information.
Approved indications
Common side effects
Key clinical trials
- Screening and Multiple Intervention on Lung Epidemics (PHASE2)
- Loteprednol Etabonate Versus Prednisolone Acetate for Anterior Chamber Granulomas (PHASE4)
- The Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment With Beta3-Adrenergic Receptor Agonists (PHASE1)
- Exercise and Mindfulness in Patients With Non-specific Chronic Low Back Pain: The BACKFIT Project (NA)
- Impact of Sugammadex Versus Neostigmine on Early Postoperative Pulmonary Function (NA)
- Impact of Artificial Intelligence Algorithm-driven Versus Standard Lifestyle Intervention in Non-Alcoholic Fatty Liver Disease - A Multicenter, Randomized, Open-label, Controlled Trial (NA)
- Repeated Bilateral Greater Occipital Nerve Blockade in Chronic Migraine and Chronic Tension-Type Headache (NA)
- Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Active drug group CI brief — competitive landscape report
- Active drug group updates RSS · CI watch RSS
- Tasly Pharmaceutical Group Co., Ltd portfolio CI
Frequently asked questions about Active drug group
What is Active drug group?
How does Active drug group work?
Who makes Active drug group?
Is Active drug group also known as anything else?
What development phase is Active drug group in?
Related
- Manufacturer: Tasly Pharmaceutical Group Co., Ltd — full pipeline
- Also known as: JS1-1-01 placebo pills; Duloxetine hydrochloride enteric coated capsule, Ropivacaine
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing